| Autor: |
S. Kosirova, D. Rubintova, J. Lacka, J. Klimas, T. Foltanova, I. Tumova |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European Pharmaceutical Journal. 69:1-8 |
| ISSN: |
2453-6725 |
| DOI: |
10.2478/afpuc-2022-0001 |
| Popis: |
AIM The aim of the study was to evaluate cardiovascular risk in patients with diabetes mellitus type 2 according to gender. METHODS The monitoring was designed as a retrospective analysis of data obtained from the documentation of the diabetic outpatients treated with the dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium–glucose co-transporter-2 (SGLT2). Cardiovascular risk was assessed according to UKPDS risk engine. RESULTS The levels of HbA1c decreased throughout the whole study. Sixty per cent of patients achieved an HbA1c level p < 0.001), stroke (p < 0.01) and fatal stroke (p < 0.01) compared to women. We found the risk of fatal CHD to be 38-fold higher in men compared to women (p < 0.01). CONCLUSION Potential cardiovascular effects of antidiabetic treatment should be clearly defined with possible different effects according to gender. We found a much higher risk in men than women, even when their glycaemic compensation was comparable. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
